RIPK1-IN-17
Based on 1 Customer Validation
RIPK1-IN-17 is an orally active, selective RIPK1 inhibitor (Kd = 17 nM) and shows no significant inhibition to RIPK3. RIPK1-IN-17 specifically inhibits necroptosis rather than apoptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation. RIPK1-IN-17 protects mice from hypothermia and death. RIPK1-IN-17 can be used for the study of necroptosis-related diseases such as inflammatory response syndrome (SIRS).
For research use only. We do not sell to patients.
- Purity : 97.09%
- CAS No.: 3033385-59-7
- Formula: C26H19F4N3O3S
- Molecular Weight:529.51
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
|
RIPK1 17 nM (Kd) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | CC50 |
>10 μM
Compound: 10
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 16 to 24 hrs by CellTiter-Glo Luminescent cell viability assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 16 to 24 hrs by CellTiter-Glo Luminescent cell viability assay
|
[PMID: 37917221] |
| HT-29 | EC50 |
0.017 μM
Compound: 10
|
Anti-necroptic activity against human HT-29 cells assessed as inhibition of TSZ (TNFalpha, Smac mimetic and z-VAD-FMK) induced necroptosis pretreated with compound followed by TSZ stimulation for 16 to 18 hrs by CellTiter-Glo Luminescent cell viability as
Anti-necroptic activity against human HT-29 cells assessed as inhibition of TSZ (TNFalpha, Smac mimetic and z-VAD-FMK) induced necroptosis pretreated with compound followed by TSZ stimulation for 16 to 18 hrs by CellTiter-Glo Luminescent cell viability as
|
[PMID: 37917221] |
In Vitro
RIPK1-IN-17 (Compound 10), which is formed by directly connecting two moieties using a biphenyl-type linker, exhibits significantly enhanced activity against necroptosis in HT-29 cells (EC50 = 0.017 μM) and demonstrates no significant cytotoxicity at the tested concentrations (CC50 > 10 μM)[1].
RIPK1-IN-17 displays significantly enhanced RIPK1 inhibitory activity (Kd = 17 nM) and demonstrates no apparent activity toward RIPK3 at a concentration of 5000 nM[1].
RIPK1-IN-17 (0.015-0.5 μM) provides dose-dependent protection against TNF-α, Cycloheximide (HY-12320), and Z-VAD-FMK (HY-16658B) (TCZ)-induced necroptosis in HT-29 cells[1].
RIPK1-IN-17 (0.015-0.5 μM) exhibits protective effects against necroptosis induced by Z-VAD-FMK (HY-16658B) at a lower concentration in murine L929 cells[1].
RIPK1-IN-17 (0.1-1 μM) shows no protection against apoptosis induced by Cycloheximide or Smac mimetic (in HT-29 cells, even at concentrations up to 1 μM[1].
RIPK1-IN-17 (1 nM-1 μM, 0-6 h) at a concentration of 1 μM over 6 hours exhibits complete inhibition of RIPK1 phosphorylation, and at doses ranging from 1 to 1000 nM for 6 hours, it inhibits the phosphorylation of RIPK1, RIPK3, and MLKL in a dose-dependent manner in HT-29 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT-29 cells
-
Concentration:1 μM
-
Incubation Time:0 h, 2 h, 4 h, 6 h
-
Result:Completely inhibited RIPK1 phosphorylation and subsequently reduced downstream phosphorylation of RIPK3 and MLKL.
-
Cell Line:HT-29 cells
-
Concentration:1 nM, 10 nM, 100 nM, 1000 nM
-
Incubation Time:6 h
-
Result:Dose-dependently inhibited TSZ-induced phosphorylation of RIPK1, RIPK3, and MLKL.
In Vivo
RIPK1-IN-17 (100 mg/kg, 200 mg/kg, oral gavage, once) shows good tolerability and safety at doses far above its effective therapeutic dose in mice, without causing acute toxic reactions or organ damage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 J mice aged 6-8 weeks injected mTNFα[1].
-
Dosage:1.25 mg/kg, 2.5 mg/kg, 5 mg/kg
-
Administration:Oral gavage, once, two hours before injection of mTNFα
-
Result:The survival rates of the SIRS mice were indicated as 70, 80, and 100%.
Significantly shielded the SIRS mice from hypothermia and death at the dosages of 1.25, 2.5, or 5 mg/kg.
Significantly reduced the levels of IL-6 and IL-1β in different tissues.
Dose-relatedly decreased the levels of IL-6 in the heart, liver, spleen, lung, kidney, intestine, and brain.
Led to a significant decrease in IL-1β levels in the spleen, lung, and intestine, which are the main organs affected in SIRS models.
Significantly decreased serum levels of IL-1β (three doses) and IL-6 (high dose).
-
Animal Model:Male C57BL/6 J mice aged 6-8 weeks[1].
-
Dosage:100 mg/kg, 200 mg/kg
-
Administration:Oral gavage, once
-
Result:No deaths or weight loss were observed after intragastric administration of the doses. Exhibited normal behavior throughout the 2-week study period.
Hematoxylin-Eosin (HE) staining assays revealed no significant pathological damage to the six vital organs (heart, liver, spleen, lung, kidney, and brain).
Chemical Information
-
CAS No. 3033385-59-7
-
Appearance Solid
-
Molecular Weight 529.51
-
Formula C26H19F4N3O3S
-
Color White to off-white
-
SMILES
O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC2=C(C=CC(C3=CC=C4N=C(SC4=C3)NC(C5CC5)=O)=C2)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)